跳至主要内容
临床试验/CTRI/2011/12/002291
CTRI/2011/12/002291已完成3 期

Determination of optimum administered activity of radionuclide (I131) for remnant ablation in patients with differentiated thyroid cancer: A randomized clinical trial

All India Institute of Medical Sciences0 个研究点目标入组 422 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
422

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients with disease confirmed to be limited to the thyroid bed only by clinical, radiological, per-operative, and post-surgical 131I scintigraphic examination and having no evidence of extra thyroidal or distant metastases at the time of radioiodine treatment.
  • Patients with tumor size (T1-3)

排除标准

  • Patients with less than total/near total thyroidectomy.
  • T4 tumor size.
  • Aggressive histology such as tall cell and columnar cell papillary carcinoma, hurthle cell carcinoma and poorly differentiated carcinoma.
  • If at any time, extra thyroidal disease in the form of either nodal or distant metastases was detected before the first-dose outcome.
  • Pregnant and breast-feeding patients.
  • Patient who were otherwise fulfilling all criteria of inclusion, but did not give consent.

研究者

相似试验